CALT - Calliditas Therapeutics, Inc. Price to Sales

Corporate company logo of Calliditas Therapeutics (CALT)

Fundamental P/S reflects a phase of commercial growth for Calliditas Therapeutics following the launch of Tarpeyo and the expansion of its sales markets. Calliditas Therapeutics aims to establish the standard of care for IgA nephropathy to prevent kidney failure. The 7.10 mark indicates the current valuation of the business, which dominates the rare kidney disease niche due to the lack of effective alternatives for patients.

CALT calliditas.se: P/S Multiple in the range 01/08/2023 - 09/28/2024

Metric breakdowns and analytics for Calliditas Therapeutics (CALT)

- current quotes and average value forecast:
Market Price calliditas.se|CALT - Consensus Target
- market capitalization statistics:
Market Value Calliditas|CALT - Enterprise Value
- shareholders' equity book value data:
Accounting Value per Share Calliditas Therapeutics|CALT - Book Capitalization|Market Capitalization to Book Value Ratio calliditas.se|CALT - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Calliditas Therapeutics|CALT - Long-Term Debt to Equity|Short-Term Debt to Equity calliditas.se|CALT - Company Aggregate Debts|Debts to Net Assets Calliditas|CALT - Company Long-Term Debts|Company Short-Term Indebtedness Calliditas Therapeutics|Interim Coverage Ratio calliditas.se
- business earnings and investment ratios data:
CALT - Net Income|Future Net Profit Calliditas Therapeutics|CALT - P/E Multiple|Forward P/E Multiple calliditas.se|CALT - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Calliditas|CALT - Operating profit before deduction of amortization|Earnings per share for the trailing year Calliditas Therapeutics|CALT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months calliditas.se|CALT - Earnings growth in current year|Expected earnings per share trend next year Calliditas Therapeutics
- issuer revenue and sales details:
CALT - Revenue and Sales Volume|Company Expected Sales Volume calliditas.se|CALT - Price-to-Revenue Ratio|Forward Price to Sales Calliditas
General company analysis:CALT, Calliditas Therapeutics, Inc.
Product sample of calliditas.se

Calliditas Therapeutics (CALT) is strengthening its global presence through strategic alliances with STADA and Everest Medicines to expand its renal disease therapy. Analyzing the price-to-sales valuation, an investor observes the ratio of market capitalization to sales volume, which determines the price of each unit of revenue and reflects the balance between the business's fundamental value and market expectations for the company's future profits.

Competing companies

TVTX - Price to Sales|Ardelyx - Market Cap to Revenue|ProKidney Corp (PROK) - Price to Sales|Akebia - P/S Multiple|Cara Corp (TVRD) - Market Cap to Revenue|DMAC: P/S Multiple|unicycive.com (UNCY) - P/S Multiple|Price-to-Revenue Ratio Rockwell Medical|Price-to-Revenue Ratio CVKD|Price-to-Revenue Ratio Conduit Pharma (CDT)|Price-to-Revenue Ratio RNLX (Renalytix, plc)|P/S Multiple ZVSA (ZyVersa Therapeutics, Inc.)